Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Enzyme Policy Update | OpenPa…
    Ask Trek AI about this page
    ModifiedMass General Brigham Health PlanPolicy N/A

    Enzyme and Metabolic Disorder Therapies

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs MassHealth UPPL medical-benefit coverage, prior authorization, and quantity-limit requirements for enzyme and metabolic disorder therapies in members with specified lysosomal, metabolic, immune, or plasminogen disorders.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEnzyme and Metabolic Disorder Therapies
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the applicable diagnosis, disease-confirming testing, specialist documentation, current weight, and drug-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Ryplazim was added with initial and reauthorization criteria.

    Xenpozyme was added with initial and reauthorization criteria for non-central nervous system manifestations of acid sphingomyelinase deficiency in adults and pediatric patients.

    Lamzede was added to the policy and requires prior authorization.

    Drugs managed through the pharmacy benefit were removed from the policy while medical-benefit drugs remained.

    Palynziq was removed from the policy and allowed to remain on the medical benefit in preparation for Prime implementation.

    The policy was updated to include the expanded Cerezyme indication for type 1 and type 3 Gaucher disease.

    Examples of positive response for Xenpozyme reauthorization were added.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    19Therapies listed
    RequiredPrior authorization
    AppliesQuantity limit
    MedicalBenefit channel
    90 daysNew-member treatment lookback

    General Coverage Criteria

    General coverage pathway

    Coverage may be authorized through either pathway below.

    Coverage pathway

    • New plan member: The member has a coverage effective date of 90 days or less, is currently receiving the requested drug, and medical records documenting current treatment are submitted.

      Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this pathway.

    • Drug-specific criteria: Authorization is requested under and meets all applicable drug-specific criteria.

    Aldurazyme initial therapy

    Aldurazyme is covered when all of the following are met.

    Aldurazyme criteria

    • Diagnosis of mucopolysaccharidosis I (MPS I).
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Diagnostic confirmation

      • Genetic testing confirms mutations in the IDUA gene.
      • Enzyme assay confirms reduced lysosomal alpha-L-iduronidase activity in peripheral blood leukocytes, plasma, or cultured fibroblasts.
    • Current member weight is provided for dosing verification.

    Cerezyme initial therapy

    Cerezyme is covered when all of the following are met.

    Cerezyme criteria

    • Diagnosis of Gaucher disease, Type I or Type 3.
    • Diagnostic confirmation

      • Genetic testing confirms a mutation in the GBA gene.
      • Enzyme assay shows reduced glucocerebrosidase activity.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Elaprase initial therapy

    Elaprase is covered when all of the following are met.

    Elaprase criteria

    • Diagnosis of Hunter syndrome (mucopolysaccharidosis II).
    • Diagnostic confirmation

      • Genetic testing confirms a mutation in the IDS gene.
      • Iduronate-2-sulfatase assay shows reduced or absent activity in serum, white blood cells, or fibroblasts.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Member weight is used to verify appropriate dosing.

    Elelyso and Vpriv initial therapy

    Elelyso and Vpriv are covered when all of the following are met.

    Elelyso and Vpriv criteria

    • Diagnosis of Gaucher disease, Type I.
    • Diagnostic confirmation

      • Genetic testing confirms a mutation in the GBA gene.
      • Enzyme assay shows reduced glucocerebrosidase activity.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Fabrazyme and Elfabrio initial therapy

    Fabrazyme is covered when all applicable criteria are met; Elfabrio also requires the Fabrazyme treatment-history criterion.

    Fabrazyme and Elfabrio criteria

    • Diagnosis of Fabry disease.
    • Diagnostic confirmation

      • Enzyme assay shows reduced or absent alpha-GAL activity in plasma, leukocytes, tears, or biopsied tissue.
      • Genetic testing confirms a mutation in the GAL gene.
      • Biomarker demonstrates increased Gb3 or GL-3 concentration.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.

    Kanuma initial therapy

    Kanuma is covered when all of the following are met.

    Kanuma criteria

    • Diagnosis of lysosomal acid lipase deficiency.
    • Diagnostic confirmation

      • Laboratory assay documents low lysosomal acid lipase activity.
      • Genetic testing confirms full or partial loss of the LAL gene.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Lamzede initial therapy

    Lamzede is covered when all of the following are met.

    Lamzede criteria

    • Diagnosis of alpha-mannosidosis.
    • Member is at least 3 years of age.≥3 years
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Genetic testing confirms alpha-mannosidosis, such as a mutation in the MAN2B1 gene.
    • Baseline measurements

    Lumizyme initial therapy

    Lumizyme is covered when all of the following are met.

    Lumizyme criteria

    • Diagnosis of Pompe disease.
    • Diagnostic confirmation

      • GAA assay shows reduced or absent activity from cultured skin fibroblasts.
      • Lymphocyte testing supports the diagnosis.
      • Blood spot assay supports the diagnosis.
      • Genetic testing confirms a mutation in the GAA gene.

    Mepsevii initial therapy

    Mepsevii is covered when all of the following are met.

    Mepsevii criteria

    • Diagnosis of mucopolysaccharidosis VII (MPS VII, Sly syndrome).
    • Genetic testing shows mutations in the beta-glucuronidase gene.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Naglazyme initial therapy

    Naglazyme is covered when all of the following are met.

    Naglazyme criteria

    • Diagnosis of mucopolysaccharidosis VI (MPS VI).
    • Enzyme assay shows reduced arylsulfatase B activity in leukocytes or fibroblasts and urine glycosaminoglycan levels are elevated.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Nexviazyme initial therapy

    Nexviazyme is covered when all of the following are met.

    Nexviazyme criteria

    • Diagnosis of late-onset Pompe disease.
    • Diagnostic confirmation

      • GAA assay shows reduced or absent activity from cultured skin fibroblasts.
      • Lymphocyte testing supports the diagnosis.
      • Blood spot assay supports the diagnosis.
      • Genetic testing confirms a mutation in the GAA gene.

    Nulibry initial therapy

    Nulibry is covered when all of the following are met.

    Nulibry criteria

    • Diagnosis of molybdenum cofactor deficiency Type A confirmed by genetic testing.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Appropriate dosing is documented.
    • Current member weight is provided for dosing verification.

    Revcovi initial therapy

    Revcovi is covered when all of the following are met.

    Revcovi criteria

    • Diagnosis of adenosine deaminase severe combined immunodeficiency (ADA-SCID).
    • Supporting laboratory or clinical evidence

      • Absent ADA enzymatic activity in lysed erythrocytes.
      • Elevated adenosine and deoxyadenosine in urine and plasma.
      • Markedly increased deoxyadenosine triphosphate (dATP) in erythrocyte lysates.
      • Significantly decreased ATP concentration in red blood cells.

    Ryplazim initial therapy

    Ryplazim is covered when all of the following are met.

    Ryplazim criteria

    • Diagnosis of plasminogen deficiency type 1 (PLGD type 1).
    • History of external and/or internal lesions and symptoms consistent with PLGD type 1, such as ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress or obstruction, or abnormal wound healing.
    • Baseline plasminogen activity is 45% or less.≤45%
    • Laboratory evidence

      • Genetic testing shows mutations in the PLG gene.

    Vimizim initial therapy

    Vimizim is covered when all of the following are met.

    Vimizim criteria

    • Diagnosis of mucopolysaccharidosis IVA (Morquio A syndrome).
    • Member is at least 5 years of age.≥5 years
    • Enzyme assay shows reduced N-acetylgalactosamine-6-sulfatase activity in blood and/or skin cells.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is provided for dosing verification.

    Ryplazim initial therapy

    Ryplazim is covered when all of the following are met.

    • Diagnosis of PLGD type 1 and history of external and/or internal lesions with compatible symptoms.
    • Baseline plasminogen activity is 45% or less.≤45%
    • Laboratory evidence

      • PLG gene mutations are demonstrated by genetic testing.
      • Plasminogen antigen level is 9 mg/dL or less.≤9 mg/dL

    Vimizim initial therapy

    Vimizim is covered when all of the following are met.

    • Diagnosis of mucopolysaccharidosis IVA (Morquio A syndrome).
    • Member is at least 5 years of age.≥5 years
    • Enzyme assay shows reduced N-acetylgalactosamine-6-sulfatase activity in blood and/or skin cells.
    • Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
    • Current member weight is documented for dosing verification.

    Xenpozyme initial therapy

    Xenpozyme is covered when all applicable criteria are met.

    Xenpozyme criteria

    • Diagnosis of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) type B or type A/B.
    • Prescriber is a specialist familiar with lysosomal storage disorders, or specialist consultation notes are provided.
    • Age-specific disease severity

      • Members ≥18 years: DLco is 70% or less of predicted normal and spleen volume is at least 6 MN.DLco ≤70%; spleen volume ≥6 MN
      • Members <18 years:

    Continuation therapy

    Continuation therapy requires the drug-specific requirements below.

    Drug-specific continuation requirements

    • Lamzede

      • Within the past 3 months, testing documents positive response in serum oligosaccharides, forced vital capacity, and one motor-function test: 3-minute stair climb or 6-minute walk.Testing within 3 months
      • Medical necessity for continued therapy is documented.
    • Ryplazim or Nulibry: A physician documents a positive response to therapy or provides clinical rationale for continued use; dosing is appropriate based on updated member weight where applicable.
    • Xenpozyme

    Lumizyme and Nexviazyme must not be used concurrently. When Nexviazyme is requested, the member must meet its separate eligibility requirements, including a weight of <30 kg and a contraindication to Lumizyme.

    Xenpozyme is not covered for members with acute or rapidly progressive neurologic abnormalities, those requiring invasive ventilatory support, or those requiring noninvasive ventilatory support while awake for more than 12 hours per day.

    Clinical Thresholds and Utilization Parameters

    Lamzede baseline motor function
    Required baseline testingOne motor function test must be documented
    Test option 13-minute stair climb test
    Test option 26-minute walk test
    Ryplazim baseline plasminogen activity
    Baseline plasminogen activity≤45%
    Applies toRyplazim initial therapy
    Measurement timingBaseline

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the MassHealth Unified Preferred Pharmacy List (UPPL) for the listed enzyme and metabolic disorder therapies when requested under the medical benefit. The program includes quantity limits; submit requests through the applicable medical-benefit process.

    • Medical benefit prior authorization applies to Aldurazyme, Cerezyme, Elaprase, Elelyso, Elfabrio, Fabrazyme, Kanuma, Lamzede, Lumizyme, Mepsevii, Naglazyme, Nexviazyme, Nulibry, Revcovi, Ryplazim, Vimizim, Vpriv, and Xenpozyme.
    • Elfabrio, Fabrazyme, Revcovi, and Ryplazim may also be available through the pharmacy benefit; consult the MassHealth Drug List for pharmacy-benefit coverage and criteria.
    Prior Authorization

    Lamzede Prior Authorization

    Lamzede requires medical-benefit prior authorization before coverage. Submit documentation supporting the diagnosis, specialist involvement, required testing, baseline measurements, age, and dosing.

    • Medical-benefit prior authorization is required for velmanase alfa-tycv (Lamzede).

    Disease and Treatment Background

    Lysosomal storage disorders result from a deficiency or absence of enzymes needed to degrade specific compounds. The resulting accumulation of these compounds can cause cellular and organ dysfunction. Enzyme replacement therapy (ERT) supplies exogenous enzymes to replace deficient enzymes and is used for conditions including Gaucher disease, Fabry disease, mucopolysaccharidosis types I, II, and VI, and Pompe disease.

    Policy Definitions

    Enzyme replacement therapy
    TermEnzyme replacement therapy (ERT)
    DefinitionExogenously supplied enzymes used to replace deficient enzymes
    Clinical contextUsed in lysosomal storage disorders
    PLGD type 1
    AbbreviationPLGD type 1
    Full termPlasminogen deficiency type 1
    Associated therapyRyplazim

    Agent-Specific Initial Therapy

    Aldurazyme initial therapy

    Aldurazyme is covered when all of the following are met.

    ALL of the following

    • Diagnosis of mucopolysaccharidosis I (MPS I).
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • ANY of the following

      • IDUA mutation testing confirms the diagnosis.
      • Reduced lysosomal alpha-L-iduronidase activity is demonstrated in peripheral blood leukocytes, plasma, or cultured fibroblasts.

    Reauthorization and Continuation

    Continuation therapy — agent-specific reauthorization requirements

    Continuation requirements differ by agent.

    Drug-specific reauthorization

    • Lamzede: Within the past 3 months, testing documents positive response in serum oligosaccharides, forced vital capacity, and one motor-function test, plus medical necessity for continued treatment.
    • Ryplazim or Nulibry: Physician documents positive response or clinical rationale for continued use; dosing is appropriate based on updated weight where applicable.
    • Xenpozyme: Documentation shows improvement from baseline in DLco, spleen volume, liver volume, platelet count, or pediatric height Z-scores, and updated member weight is provided.

    Dose and Quantity Limits

    Ryplazim quantity limit
    Maximum dose per administration≤6.6 mg/kg
    Dosing frequencyEvery two to four days
    Quantity-limit drugRyplazim
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEnzyme and Metabolic Disorder Therapies
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the applicable diagnosis, disease-confirming testing, specialist documentation, current weight, and drug-specific criteria.
    SourceLink
    On This Page
    General Coverage CriteriaClinical Thresholds and Utilization ParametersAuthorization, Documentation, and Denial RisksDisease and Treatment BackgroundPolicy DefinitionsAgent-Specific Initial TherapyReauthorization and ContinuationDose and Quantity Limits
    Elelyso only: Member is at least 4 years of age.
  1. Current member weight is provided for dosing verification.
  2. Elfabrio only: There is an inadequate response, adverse reaction, or contraindication to Fabrazyme.
  3. Baseline serum oligosaccharides are documented.
  4. Baseline forced vital capacity is documented.
  5. Motor function test

    • Baseline 3-minute stair climb test is documented.
    • Baseline 6-minute walk test is documented.
  6. Current member weight is provided for dosing verification.
  7. Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
  8. Current member weight is provided for dosing verification.
  9. Member is at least 1 year of age.≥1 year
  10. Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
  11. Current member weight is provided for dosing verification.
  12. Member weighs less than 30 kg and has a contraindication to Lumizyme.<30 kg
  13. Absent or extremely low N adenosylhomocysteine hydrolase in red blood cells.
  14. Severe T-cell deficiency manifested by lymphopenia and poor T-cell responses to mitogens and antigens.
  15. Absent thymic shadow on chest radiograph.
  16. Prescriber is a specialist in genetic or metabolic diseases, or specialist consultation notes are provided.
  17. Current member weight is provided for dosing verification.
  18. Plasminogen antigen level is 9 mg/dL or less.≤9 mg/dL
  19. Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
  20. Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days
    Spleen volume is at least 5 MN.
    ≥5 MN
  21. Member does not have acute or rapidly progressive neurologic abnormalities.
  22. Member does not require invasive ventilatory support and does not require noninvasive ventilatory support while awake for more than 12 hours a day.Awake noninvasive support ≤12 hours/day
  23. Current member weight is provided for dosing verification.
  24. Appropriate dosing is documented.
  25. Documentation shows improvement from baseline in DLco, spleen volume, liver volume, platelet count, or height Z-scores in children.
  26. Updated member weight is provided.
  27. All other drugs: Prescriber resubmission infers a positive response to therapy.
  28. Ryplazim plasminogen antigen
    Plasminogen antigen threshold≤9 mg/dL
    Evidence pathwayAlternative to PLG gene mutation testing
    Applies toRyplazim
    Ryplazim requested dose
    Maximum dose≤6.6 mg/kg
    FrequencyEvery two to four days
    Applies toRyplazim requested dose
    Nexviazyme age
    Minimum age≥1 year
    TherapyNexviazyme
    Disease indicationLate-onset Pompe disease
    Nexviazyme weight restriction
    Maximum eligible weight<30 kg
    Additional requirementContraindication to Lumizyme
    Concurrent useLumizyme and Nexviazyme should not be used concurrently
    Elelyso age
    Minimum age≥4 years
    TherapyElelyso
    IndicationGaucher disease Type I
    Lamzede age
    Minimum age≥3 years
    TherapyLamzede
    IndicationAlpha-mannosidosis
    Vimizim age
    Minimum age≥5 years
    TherapyVimizim
    IndicationMucopolysaccharidosis IVA (Morquio A syndrome)
    Baseline plasminogen activity
    Baseline plasminogen activity≤45%
    Required forRyplazim eligibility
    Measurement pointBaseline
    Ryplazim dose
    Dose limit≤6.6 mg/kg
    Dosing frequencyEvery two to four days
    DrugRyplazim
    Plasminogen antigen level
    Antigen threshold≤9 mg/dL
    Testing evidencePlasminogen antigen level
    Alternative evidencePLG gene mutations on genetic testing
    Adult Xenpozyme DLco
    Adult age groupMembers ≥18 years of age
    DLco threshold≤70% of predicted normal value
    Required with DLcoSpleen volume ≥6 MN
    Adult Xenpozyme spleen volume
    Adult spleen-volume threshold≥6 MN
    Adult age groupMembers ≥18 years of age
    Required with spleen volumeDLco ≤70% of predicted normal value
    Pediatric Xenpozyme spleen volume
    Pediatric spleen-volume threshold≥5 MN
    Pediatric age groupMembers <18 years of age
    TherapyXenpozyme
    Awake noninvasive ventilatory support
    Daily-use restrictionMust not be required for more than 12 hours a day
    Support typeNoninvasive ventilatory support while awake
    TherapyXenpozyme
  29. Use the medical-benefit contact process for requests; pharmacy-benefit coverage and criteria may differ.
  30. Documentation Required

    Document Current Treatment for New Members

    For a member who has been covered by the plan for 90 days or less, submit medical records showing that the member is currently receiving the requested drug. Do not rely on treatment obtained only through samples or a manufacturer patient-assistance program.

    • The coverage-effective date must be less than or equal to 90 days before the request.
    • Records should document current treatment with the requested product and should exclude treatment obtained as samples or through manufacturer patient assistance.
    Documentation Required

    Submit Complete Clinical Documentation

    Submit records that establish the drug-specific diagnosis, required genetic or enzyme testing, specialist prescribing or consultation, current weight for dose verification, and any product-specific age, baseline-measurement, dose, or clinical requirements.

    • Aldurazyme: MPS I; IDUA mutation or reduced alpha-L-iduronidase activity; genetics/metabolic specialist; current weight.
    • Cerezyme: Type I or Type 3 Gaucher disease; GBA mutation or reduced glucocerebrosidase activity; genetics/metabolic specialist; current weight.
    • Elaprase: Hunter syndrome/MPS II; IDS mutation or reduced/absent iduronate-2-sulfatase activity; genetics/metabolic specialist; weight-based dosing.
    • Elelyso and Vpriv: Type I Gaucher disease; GBA mutation or reduced glucocerebrosidase activity; specialist; current weight. Elelyso also requires age ≥4 years.
    • Fabrazyme: Fabry disease; reduced or absent α-GAL activity, GAL mutation, or elevated Gb3/GL-3 biomarker; specialist; current weight.
    • Kanuma: lysosomal acid lipase deficiency; low LAL activity or full/partial LAL-gene loss; specialist; current weight.
    • Lamzede: alpha-mannosidosis; age ≥3 years; specialist; MAN2B1 or other confirmatory genetic testing; baseline serum oligosaccharides, forced vital capacity, and either the 3-minute stair-climb or 6-minute walk test; current weight.
    • Lumizyme: Pompe disease; reduced/absent GAA activity by fibroblast, lymphocyte, or blood-spot testing, or GAA mutation; specialist; current weight.
    • Mepsevii: MPS VII/Sly syndrome; beta-glucuronidase-gene mutations; specialist; current weight.
    • Naglazyme: MPS VI; reduced arylsulfatase B activity with elevated urine GAG levels; specialist; current weight.
    • Nexviazyme: late-onset Pompe disease; qualifying GAA assay, lymphocyte, blood-spot, or GAA genetic testing; age ≥1 year; specialist; current weight; weight <30 kg and contraindication to Lumizyme.
    • Nulibry: genetically confirmed MoCD type A; specialist; appropriate dosing and current weight.
    • Revcovi: ADA-SCID; qualifying laboratory evidence such as absent ADA activity, elevated adenosine/deoxyadenosine, increased dATP, reduced RBC ATP, absent or very low erythrocyte SAH hydrolase, severe T-cell deficiency, or absent thymic shadow; specialist; current weight.
    • Ryplazim: PLGD type 1; compatible lesions and symptoms; baseline plasminogen activity ≤45%; PLG mutation or plasminogen antigen ≤9 mg/dL; dose ≤6.6 mg/kg every 2–4 days.
    • Vimizim: MPS IVA/Morquio A; age ≥5 years; reduced N-acetylgalactosamine-6-sulfatase activity in blood or skin cells; specialist; current weight.
    • Xenpozyme: non-CNS ASMD type B or A/B; specialist; required DLco/spleen-volume measurements by age; no acute or rapidly progressive neurologic abnormalities; no prohibited ventilatory support; current weight and appropriate dosing.
    Documentation Required

    Ryplazim Diagnostic Testing

    For Ryplazim, document the diagnostic evidence for plasminogen deficiency type 1 and the clinical manifestations supporting treatment.

    • Provide genetic testing showing mutations in the PLG gene or plasminogen antigen levels ≤9 mg/dL.
    • Document a history of external or internal lesions and compatible symptoms, such as ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress or obstruction, or abnormal wound healing.
    • Submit baseline plasminogen activity ≤45% and confirm the requested dose is ≤6.6 mg/kg every two to four days.
    Documentation Required

    Vimizim Testing and Weight

    For Vimizim, submit enzyme-assay evidence of reduced N-acetylgalactosamine-6-sulfatase activity and the member’s current weight for dose verification.

    • Document MPS IVA (Morquio A syndrome).
    • Member must be ≥5 years of age.
    • Provide testing from blood and/or skin cells, specialist involvement or consultation notes, and current weight.

    Unsupported block type: documentation

    Documentation Required

    Lamzede Continuation Documentation

    For Lamzede reauthorization, submit recent objective evidence of benefit and the medical necessity for continued treatment.

    • Provide testing from within the past 3 months showing a positive response in serum oligosaccharides, forced vital capacity, and either the 3-minute stair-climb or 6-minute walk test.
    • Document medical necessity for continuation, such as disease stabilization or reduction in expected motor decline.
    Documentation Required

    Xenpozyme Continuation Documentation

    For Xenpozyme reauthorization, submit updated clinical evidence demonstrating benefit from baseline and the member’s current weight.

    • Document improvement from baseline in DLco, spleen volume, liver volume, platelet count, or height Z-scores for children.
    • Provide updated member weight to support dose verification.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: step_therapy

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    ADA-SCID
    AbbreviationADA-SCID
    Full termAdenosine deaminase severe combined immunodeficiency
    Associated therapyRevcovi
    Current member weight is provided for dosing verification.

    Cerezyme initial therapy

    Cerezyme is covered when all of the following are met.

    ALL of the following

    • Diagnosis of Gaucher disease, Type I or Type 3.
    • ANY of the following

      • GBA mutation is confirmed by genetic testing.
      • Reduced glucocerebrosidase activity is demonstrated by enzyme assay.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Elaprase initial therapy

    Elaprase is covered when all of the following are met.

    ALL of the following

    • Diagnosis of Hunter syndrome (MPS II).
    • ANY of the following

      • IDS mutation is confirmed by genetic testing.
      • Iduronate-2-sulfatase activity is reduced or absent in serum, white blood cells, or fibroblasts.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Member weight is used to verify appropriate dosing.

    Elelyso and Vpriv initial therapy

    Elelyso and Vpriv are covered when all of the following are met.

    ALL of the following

    • Diagnosis of Gaucher disease, Type I.
    • ANY of the following

      • GBA mutation is confirmed by genetic testing.
      • Reduced glucocerebrosidase activity is demonstrated by enzyme assay.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.
    • For Elelyso, member is at least 4 years old.≥4 years

    Fabrazyme and Elfabrio initial therapy

    Fabrazyme and Elfabrio are covered when all applicable criteria are met.

    ALL of the following

    • Diagnosis of Fabry disease.
    • ANY of the following

      • Reduced or absent alpha-GAL activity is shown by enzyme assay.
      • GAL gene mutation is confirmed by genetic testing.
      • Gb3 or GL-3 concentration is increased.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.
    • For Elfabrio, there is inadequate response, adverse reaction, or contraindication to Fabrazyme.

    Kanuma initial therapy

    Kanuma is covered when all of the following are met.

    ALL of the following

    • Diagnosis of lysosomal acid lipase deficiency.
    • ANY of the following

      • Low lysosomal acid lipase activity is documented by laboratory assay.
      • Full or partial loss of the LAL gene is confirmed by genetic testing.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Lamzede initial therapy

    Lamzede is covered when all of the following are met.

    ALL of the following

    • Diagnosis of alpha-mannosidosis.
    • Member is at least 3 years old.≥3 years
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Genetic testing confirms alpha-mannosidosis.
    • Baseline serum oligosaccharides, forced vital capacity, and one motor-function test are documented.
    • Current member weight is provided for dosing verification.

    Lumizyme initial therapy

    Lumizyme is covered when all of the following are met.

    ALL of the following

    • Diagnosis of Pompe disease.
    • ANY of the following

      • Qualifying GAA enzyme assay, lymphocyte testing, or blood spot assay supports the diagnosis.
      • Genetic testing confirms a GAA mutation.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Mepsevii initial therapy

    Mepsevii is covered when all of the following are met.

    ALL of the following

    • Diagnosis of MPS VII (Sly syndrome).
    • Beta-glucuronidase gene mutations are demonstrated by genetic testing.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Naglazyme initial therapy

    Naglazyme is covered when all of the following are met.

    ALL of the following

    • Diagnosis of MPS VI.
    • Reduced arylsulfatase B activity and elevated urine glycosaminoglycan levels are documented.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Nexviazyme initial therapy

    Nexviazyme is covered when all of the following are met.

    ALL of the following

    • Diagnosis of late-onset Pompe disease.
    • ANY of the following

      • Qualifying GAA enzyme assay, lymphocyte testing, or blood spot assay supports the diagnosis.
      • Genetic testing confirms a GAA mutation.
    • Member is at least 1 year old.≥1 year
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.
    • Weight is less than 30 kg and there is a contraindication to Lumizyme.<30 kg

    Nulibry initial therapy

    Nulibry is covered when all of the following are met.

    ALL of the following

    • Genetically confirmed molybdenum cofactor deficiency Type A.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Appropriate dosing is documented.
    • Current member weight is provided for dosing verification.

    Revcovi initial therapy

    Revcovi is covered when all of the following are met.

    ALL of the following

    • Diagnosis of ADA-SCID.
    • Qualifying evidence: At least one listed ADA, adenosine/deoxyadenosine, dATP, ATP, N adenosylhomocysteine hydrolase, T-cell deficiency, or chest-radiograph finding is documented.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is provided for dosing verification.

    Ryplazim initial therapy

    Ryplazim is covered when all of the following are met.

    ALL of the following

    • PLGD type 1 with compatible lesion and symptom history.
    • Baseline plasminogen activity is 45% or less.≤45%
    • ANY of the following

      • PLG mutation is demonstrated by genetic testing.
      • Plasminogen antigen is 9 mg/dL or less.≤9 mg/dL
    • Dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days

    Vimizim initial therapy

    Vimizim is covered when all of the following are met.

    ALL of the following

    • MPS IVA (Morquio A syndrome).
    • Member is at least 5 years old.≥5 years
    • Reduced N-acetylgalactosamine-6-sulfatase activity is demonstrated by enzyme assay in blood or skin cells.
    • Genetic or metabolic disease specialist prescriber or specialist consultation.
    • Current member weight is documented for dosing verification.

    Ryplazim initial therapy — genetic or antigen-level laboratory evidence

    Ryplazim initial therapy requires all of the following.

    ALL of the following

    • PLGD type 1 diagnosis with compatible lesions and symptoms.
    • Baseline plasminogen activity is 45% or less.≤45%
    • Laboratory evidence

      • PLG gene mutations are demonstrated by genetic testing.
      • Plasminogen antigen is 9 mg/dL or less.≤9 mg/dL
    • Requested dose is no more than 6.6 mg/kg every two to four days.≤6.6 mg/kg every 2–4 days

    Vimizim initial therapy — all listed criteria

    Vimizim initial therapy requires all of the following.

    ALL of the following

    • Diagnosis of Morquio A syndrome.
    • Member is at least 5 years of age.≥5 years
    • Enzyme assay demonstrates reduced N-acetylgalactosamine-6-sulfatase activity.
    • Genetic or metabolic disease specialist involvement is documented.
    • Current member weight is documented for dosing verification.

    Xenpozyme initial therapy — general and age-specific criteria

    Xenpozyme initial therapy requires all general criteria and one age-specific disease-severity branch.

    ALL of the following

    • ASMD type B or type A/B with non-central nervous system manifestations.
    • Specialist involvement or consultation is documented.
    • Age-specific severity

      • Members ≥18 years: DLco is 70% or less of predicted normal and spleen volume is at least 6 MN.DLco ≤70%; spleen volume ≥6 MN
      • Members <18 years: Spleen volume is at least 5 MN.≥5 MN
    • No acute or rapidly progressive neurologic abnormalities.
    • No invasive ventilatory support and no awake noninvasive ventilatory support for more than 12 hours per day.Awake noninvasive support ≤12 hours/day
    • Current weight and appropriate dosing are documented.
    All other drugs: Prescriber resubmission infers a positive response to therapy.